Balb cj mice

P2X₇^−/− mice on a balb/cj background (over 10 generation back crossed) were bred at the Institute of Biomedicine, Aarhus University and matched with either ${\text{P}2\text{X}}_7^{+/+}$ littermates from heterozygous breeding or balb/cj mice from Janvier Labs (Saint-Berthevin, France). The ${\text{P}2\text{X}}_7^{-/-}$ mice were originally developed by GlaxoSmithKline and bred into the balb/cj background. Animal experiments with the P2X antagonists, BBG, were performed on balb/cj mice from Janvier Labs.
P2X₁and P2X₄ wild type and knockout mice were bred at the Institute of Biomedicine, Aarhus University, by heterozygous breeding and littermates were used. P2X₁ mice were on a C57BL/6J background and P2X₄ were on a mixed background (C57BL6.b6129s). All P2X mice used in this study were 8–10 week old males with a weight of 25.1 ± 0.8 g.
Caspase-8/RIPK-3^−DKO mice were bred in the Kiel facility, Germany, as published (Linkermann et al., 2013 (link)), and matched with C57BL/6N mice from either Charles River, Sulzfeld or Janvier Labs. The authors would like to thank NR Jorgensen for providing the P2X₇ mice, J Leipziger for providing the P2X₄ mice, D Green for providing the casp8/RIPK3^DKO (Oberst et al., 2011 (link)), V. Dixit and K. Newton (Genentech) for providing RIPK3 deficient mice (Newton et al., 2004 (link)) and R Hakim for casp8 heterozygous mice (Salmena et al., 2003 (link)).

Female C57BL/6JRj or BALB/cJ mice (Janvier, Le Genest Saint Isle, France) were used between the age of 7 and 10 weeks. Seven mice were housed per cage. Mice were immunized subcutaneously (s.c.) at the basis of the tail with the indicated amounts of LV contained in 200 µl. When indicated, mice were immunized intranasally (i.n.) with the indicated amounts of LV contained in 20 µl, as previously detailed^{28 (link)}. The i.n. administration was realized under anesthesia, obtained by peritoneal injection of a mixture of Xylazine (Rompun, 10 mg/kg) and Ketamine (Imalgene, 100 mg/kg).